Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 12/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 9/20 | 1.00 |
| ▸ | PRKACA | P17612 | 4/20 | 1.00 |
| ▸ | HTT | P42858 | 1/20 | 0.83 |
| ▸ | MEN1 | O00255 | 2/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.77 |
| ▸ | MAPT | P10636 | 2/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.77 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.74 |
| ▸ | RAB9A | P51151 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL438700 | 0.88 | CYP3A4 (1.00) | ROCK1CYP3A4PRKACAHTTMEN1 | |
| SCHEMBL3257500 | 0.88 | ROCK1 (0.78) | ROCK1CYP3A4PRKACAHTTMEN1 | |
| SCHEMBL439520 | 0.88 | CYP3A4 (1.00) | ROCK1CYP3A4PRKACAHTTMEN1 | |
| SCHEMBL439202 | 0.87 | CYP3A4 (1.00) | ROCK1CYP3A4PRKACAHTTMEN1 | |
| SCHEMBL436413 | 0.87 | CYP3A4 (1.00) | ROCK1CYP3A4PRKACAHTTMEN1 | |
| SCHEMBL436411 | 0.87 | CYP3A4 (1.00) | ROCK1CYP3A4PRKACAHTTMEN1 | |
| SCHEMBL13357587 | 0.87 | ROCK1 (1.00) | ROCK1CYP3A4PRKACAHTTMEN1 | |
| SCHEMBL439512 | 0.86 | ROCK1 (1.00) | ROCK1CYP3A4PRKACAHTTMEN1 | |
| SCHEMBL3254509 | 0.86 | ROCK1 (0.75) | ROCK1CYP3A4PRKACAHTTROCK2 | |
| SCHEMBL2558208 | 0.85 | ROCK1 (1.00) | ROCK1CYP3A4PRKACAROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1558607-B1 | COMPOSITIONS USEFUL AS INHIBITORS OF ROCK AND OTHER PROTEIN KINASES | VERTEX PHARMA (US) | 2010-05-05 | — | — | EP | disclosed |
| EP-1558607-A1 | COMPOSITIONS USEFUL AS INHIBITORS OF ROCK AND OTHER PROTEIN KINASES | Vertex Pharmaceuticals Incorporated (US) | 2005-08-03 | — | — | EP | disclosed |
| US-20040122016-A1 | Compositions useful as inhibitors of rock and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2004-06-24 | — | — | US | disclosed |
| WO-2004041813-A1 | COMPOSITIONS USEFUL AS INHIBITORS OF ROCK AND OTHER PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2004-05-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122016-A1 | Compositions useful as inhibitors of rock and other protein kinases | ROCK1, ROCK2, PRKCH | ROCK1 1/4885CYP3A4 4740/4885PRKACA 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.